LYRA

Lyra Therapeutics

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$33.8M

Burn Rate (Qtr)

$11.9M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

LYR-210 (anti-inflammatory implantable drug matrix)

Rhinosinusitis, Chronic rhinosinusitis, Neurological disorder, Parkinson's disease

Phase 3

Update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

LYR-220 (Long-acting Mometasone Furoate)

Chronic rhinosinusitis

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

LYRA

BPIQ_Logo_RGB-01.jpg

Company Profile

Lyra Therapeutics is a clinical-stage company developing medicines precisely designed to target ear, nose and throat (ENT) diseases. Our goal is to transform the ENT treatment paradigm by providing effective solutions for physicians and new treatment options for their patients.

Recent Posts

See what the community is saying - click to see full post.